Comparing Antipsychotic Medications in LBD Over Time
A Pragmatic Randomized Trial Comparing Antipsychotics in Lewy Body Disease
The University of Texas Health Science Center at San Antonio
94 participants
Apr 22, 2022
INTERVENTIONAL
Conditions
Summary
The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Dosage choice and further medication management will be at the discretion of the treating clinician, per routine clinical practice.
Dosage choice and further medication management will be at the discretion of the treating clinician, per routine clinical practice.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05590637